Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › ACAD
RICE HALL JAMES & ASSOCIATES, LLC position in ACAD
ACADIA PHARMACEUTICALS INC · Health Care
RICE HALL JAMES & ASSOCIATES, LLC reported holding 605,577 shares of ACAD (ACADIA PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$12.2M, representing 0.65% of its reported portfolio and ranking #48 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed ACAD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RICE HALL JAMES & ASSOCIATES, LLC's ACAD position evolved
RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in ACAD in Q3 2023 at 696,065 shares (US$14.5M). The position peaked in Q4 2023 at 692,852 shares, worth US$21.7M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 2 time(s), trimmed it 7 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 605,577 shares valued at US$12.2M — a reduction of -13,310 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 696.07K | $14.51M | New |
| Q4 2023 | 692.85K | $21.69M | Hold |
| Q1 2024 | 664.56K | $12.29M | Reduce |
| Q2 2024 | 742.93K | $12.07M | Add |
| Q3 2024 | 717.15K | $11.03M | Reduce |
| Q4 2024 | 681.54K | $12.51M | Reduce |
| Q1 2025 | 672.22K | $11.17M | Reduce |
| Q2 2025 | 669.81K | $14.45M | Hold |
| Q3 2025 | 614.94K | $13.12M | Reduce |
| Q4 2025 | 603.74K | $16.13M | Reduce |
| Q1 2026 | 617.49K | $13.75M | Add |
| Q2 2026 | 618.89K | $15.66M | Hold |
| Q3 2026 | 605.58K | $12.20M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACAD and 13F data
ACAD (ACADIA PHARMACEUTICALS INC) is a Health Care company. 26 other funds we track also report a position in ACAD — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.09B), RTW INVESTMENTS, LP (US$144.0M), Palo Alto Investors LP (US$72.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACAD
- BAKER BROS. ADVISORS LP 42.91M sh · $1.09B · Q2 2026
- RTW INVESTMENTS, LP 7.14M sh · $143.96M · Q3 2026
- Palo Alto Investors LP 2.86M sh · $72.46M · Q2 2026
- BRAIDWELL LP 1.65M sh · $41.65M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.44M sh · $36.39M · Q2 2026
More on RICE HALL JAMES & ASSOCIATES, LLC
FAQ
How long has RICE HALL JAMES & ASSOCIATES, LLC held ACAD?
RICE HALL JAMES & ASSOCIATES, LLC has disclosed ACAD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RICE HALL JAMES & ASSOCIATES, LLC's current position in ACAD?
As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 605.58K shares of ACAD (ACADIA PHARMACEUTICALS INC), valued at $12.20M, representing 0.65% of its reported portfolio and ranking #48.
Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling ACAD?
In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC reduced its position in ACAD. The position peaked in Q4 2023 at 692.85K shares.
Which other funds hold ACAD?
Other major institutional holders of ACAD include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Palo Alto Investors LP, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.